Alton O. Sartor, M.D.

Oliver Sartor, M.D., is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at Mayo Clinic in Rochester, Minnesota. Dr. Sartor serves as chair of the Genitourinary Cancer Disease Group and director of Radiopharmaceutical Clinical Trials across the enterprise for Mayo Clinic Comprehensive Cancer Center. Dr. Sartor joined the staff of Mayo Clinic in April 2023.

After receiving his M.D. from Tulane University School of Medicine in New Orleans, Dr. Sartor completed his internal medicine residency, followed by a fellowship at the National Cancer Institute in Bethesda, Maryland, where he was junior faculty. He later returned to New Orleans, eventually becoming chief of the Hematology/Oncology Section and director of the Stanley S. Scott Cancer Center at Louisiana State University Health Sciences Center and co-director of the Louisiana Cancer Research Consortium. He later joined the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute and Harvard Medical School in Boston before returning to Tulane University as the Laborde Professor for Cancer Research in the departments of Medicine and Urology, medical director of the Tulane Cancer Center, and associate dean for Oncology for the Tulane University School of Medicine.

Dr. Sartor has focused predominantly on clinical and translational aspects of prostate cancer. He has published over 500 peer-reviewed manuscripts and established multidisciplinary collaborations with urology, nuclear medicine and radiation oncology. He was chair of the Department of Defense Integration Panel for Prostate Cancer and was a member of the Board of Scientific Counselors at the National Cancer Institute. He has been a principal or co-principal investigator on four pivotal multi-institutional trials leading to Food and Drug Administration approvals for new drugs to treat advanced prostate cancer. He is vice chair of the Genitourinary Cancer Committee for NRG Oncology.